Adma Biologics Inc (NASDAQ: ADMA) is 34.81% higher on its value in year-to-date trading and has touched a low of $6.72 and a high of $25.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $23.71 in the last trading session, with the day’s loss setting it -0.59%.
Currently trading at $23.12, the stock is 6.56% and 17.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.04 million and changing -2.49% at the moment leaves the stock 28.21% off its SMA200. ADMA registered 243.03% gain for a year compared to 6-month gain of 41.75%.
The stock witnessed a 28.37% loss in the last 1 month and extending the period to 3 months gives it a 36.80%, and is -4.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.74% over the week and 7.27% over the month.
Adma Biologics Inc (ADMA) has around 685 employees, a market worth around $5.52B and $426.45M in sales. Current P/E ratio is 28.56 and Fwd P/E is 23.20. Profit margin for the company is 46.35%. Distance from 52-week low is 244.05% and -9.93% from its 52-week high. The company has generated returns on investments over the last 12 months (45.98%).
The EPS is expected to grow by 45.61% this year.
Adma Biologics Inc (ADMA) Top Institutional Holders
The shares outstanding are 236.62M, and float is at 230.23M with Short Float at 5.76%.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.0221% of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.2459 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.6668% and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8401 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Grossman Adam S, the company’s President and CEO. SEC filings show that Grossman Adam S sold 21,000 shares of the company’s common stock on Apr 15 ’25 at a price of $21.46 per share for a total of $0.45 million. Following the sale, the insider now owns 2.06 million shares.
Adma Biologics Inc disclosed in a document filed with the SEC on Mar 19 ’25 that Grossman Adam S (President and CEO) sold a total of 21,000 shares of the company’s common stock. The trade occurred on Mar 19 ’25 and was made at $18.92 per share for $0.4 million. Following the transaction, the insider now directly holds 2.06 million shares of the ADMA stock.
Still, SEC filings show that on Mar 19 ’25, Grossman Adam S (Director and Officer) Proposed Sale 84,000 shares at an average price of $18.71 for $1.57 million. The insider now directly holds shares of Adma Biologics Inc (ADMA).
